Prot# SL0010: A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter Study of The Efficacy and Safety of four 12-week Treatment Cycles (48 weeks total) Of Epratuzumab in Systematic Lupus Erythematosus Subjects With Moderate To Severe Disease